➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Moodys
Johnson and Johnson
Medtronic

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SUBLOCADE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sublocade

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03604159 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept Not yet recruiting New York University School of Medicine Phase 4 2018-08-01 This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.
NCT03744663 Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films Not yet recruiting Wake Forest University Health Sciences Phase 2 2018-11-01 While substance use disorders have been found to have relapse rates on part with other chronic illnesses such as hypertension and asthma long term abstinence remains elusive for many. The FDA has recently approve a long acting subcutaneous injectable formulation of buprenorphine. This study aims to determine the feasibility of enrolling and randomizing patients seeking treatment at an outpatient substance abuse clinic to buprenorphine/naloxone films which dissolve under the tongue vs. long acting buprenorphine injection with all other treatment aspects held constant. The study also aims to determine the effectiveness of monthly injections of Sublocade® compared to daily oral Suboxone® SL therapy in the treatment of moderate to severe opioid use disorder after twenty-four weeks of treatment.
NCT03818399 Virginia Opioid Overdose Treatment InitiatVE Recruiting Indivior Inc. Phase 3 2019-01-04 This is a Phase 3b, open-label study in patients that present to the ED for an opioid OD and receive treatment with an opioid antagonist. The study is designed to determine effect of SUBLOCADE on repeat overdose and death compared to historical control data. The study will assess subjects that receive acute administration of SUBOXONE sublingual film in the Emergency Department (ED) followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, compared to historical control data from electronic health records.
NCT03818399 Virginia Opioid Overdose Treatment InitiatVE Recruiting Virginia Commonwealth University Phase 3 2019-01-04 This is a Phase 3b, open-label study in patients that present to the ED for an opioid OD and receive treatment with an opioid antagonist. The study is designed to determine effect of SUBLOCADE on repeat overdose and death compared to historical control data. The study will assess subjects that receive acute administration of SUBOXONE sublingual film in the Emergency Department (ED) followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, compared to historical control data from electronic health records.
NCT03861338 An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder Recruiting New York State Psychiatric Institute Phase 1/Phase 2 2019-03-01 The proposed study is a 12-week, open-label pilot study of sublocade (extended-release burprenorphine, BXR) as treatment for opiate use disorder (OUD) testing positive for Highly Potent Synthetic Opioids (HPSO). We plan to enroll 10 participants into the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sublocade

Condition Name

Condition Name for Sublocade
Intervention Trials
Opioid-use Disorder 3
Opioid Use Disorder, Severe 1
Opioid Use Disorder, Moderate 1
Opioid Use Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sublocade
Intervention Trials
Disease 3
Substance-Related Disorders 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sublocade

Trials by Country

Trials by Country for Sublocade
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sublocade
Location Trials
New York 1
Virginia 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sublocade

Clinical Trial Phase

Clinical Trial Phase for Sublocade
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sublocade
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sublocade

Sponsor Name

Sponsor Name for Sublocade
Sponsor Trials
Indivior Inc. 3
New York State Psychiatric Institute 2
New York University School of Medicine 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sublocade
Sponsor Trials
Other 5
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Dow
Johnson and Johnson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.